Compare FNWB & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | LONA |
|---|---|---|
| Founded | 1923 | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.3M | 81.5M |
| IPO Year | 2012 | N/A |
| Metric | FNWB | LONA |
|---|---|---|
| Price | $11.01 | $7.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $13.50 | $10.00 |
| AVG Volume (30 Days) | 21.4K | ★ 28.2K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 36.00 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $4.21 |
| 52 Week High | $12.52 | $14.21 |
| Indicator | FNWB | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 48.64 |
| Support Level | $9.37 | $6.86 |
| Resistance Level | $11.51 | $9.78 |
| Average True Range (ATR) | 0.37 | 0.45 |
| MACD | -0.16 | 0.06 |
| Stochastic Oscillator | 4.59 | 85.16 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.